<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/89CB4B03-B75B-40DE-96FE-CE7ED9289F6E"><gtr:id>89CB4B03-B75B-40DE-96FE-CE7ED9289F6E</gtr:id><gtr:name>Molecules of Man AB</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/C7FBE408-C743-4AAC-9BC6-65E14BC8D2FD"><gtr:id>C7FBE408-C743-4AAC-9BC6-65E14BC8D2FD</gtr:id><gtr:name>Karolinska Institute</gtr:name><gtr:address><gtr:line1>Administration</gtr:line1><gtr:line4>Stockholm</gtr:line4><gtr:postCode>SE-171 77</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Sweden</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/9DD91628-E98B-4CA1-A0EF-04613710DFFC"><gtr:id>9DD91628-E98B-4CA1-A0EF-04613710DFFC</gtr:id><gtr:name>CEINGE Biotecnologie Avanzate</gtr:name><gtr:address><gtr:line1>via Comunale Magherita 482</gtr:line1><gtr:postCode>80145</gtr:postCode><gtr:region>Unknown</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/CB597297-71EC-49CA-868E-47371DFC4207"><gtr:id>CB597297-71EC-49CA-868E-47371DFC4207</gtr:id><gtr:name>Oxford Radcliffe Hospitals NHS Trust</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/57150975-2FFC-442F-A99E-ABD25A46F8D2"><gtr:id>57150975-2FFC-442F-A99E-ABD25A46F8D2</gtr:id><gtr:name>Pasteur Institute, Paris</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/936D002F-A8D1-4A93-AE5D-825ED0903D8D"><gtr:id>936D002F-A8D1-4A93-AE5D-825ED0903D8D</gtr:id><gtr:name>University of Nottingham</gtr:name><gtr:department>Inst of Infections and Immunity</gtr:department><gtr:address><gtr:line1>University Park</gtr:line1><gtr:line4>Nottingham</gtr:line4><gtr:line5>Nottinghamshire</gtr:line5><gtr:postCode>NG7 2RD</gtr:postCode><gtr:region>East Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/936D002F-A8D1-4A93-AE5D-825ED0903D8D"><gtr:id>936D002F-A8D1-4A93-AE5D-825ED0903D8D</gtr:id><gtr:name>University of Nottingham</gtr:name><gtr:address><gtr:line1>University Park</gtr:line1><gtr:line4>Nottingham</gtr:line4><gtr:line5>Nottinghamshire</gtr:line5><gtr:postCode>NG7 2RD</gtr:postCode><gtr:region>East Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/89CB4B03-B75B-40DE-96FE-CE7ED9289F6E"><gtr:id>89CB4B03-B75B-40DE-96FE-CE7ED9289F6E</gtr:id><gtr:name>Molecules of Man AB</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/C7FBE408-C743-4AAC-9BC6-65E14BC8D2FD"><gtr:id>C7FBE408-C743-4AAC-9BC6-65E14BC8D2FD</gtr:id><gtr:name>Karolinska Institute</gtr:name><gtr:address><gtr:line1>Administration</gtr:line1><gtr:line4>Stockholm</gtr:line4><gtr:postCode>SE-171 77</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Sweden</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/9DD91628-E98B-4CA1-A0EF-04613710DFFC"><gtr:id>9DD91628-E98B-4CA1-A0EF-04613710DFFC</gtr:id><gtr:name>CEINGE Biotecnologie Avanzate</gtr:name><gtr:address><gtr:line1>via Comunale Magherita 482</gtr:line1><gtr:postCode>80145</gtr:postCode><gtr:region>Unknown</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/CB597297-71EC-49CA-868E-47371DFC4207"><gtr:id>CB597297-71EC-49CA-868E-47371DFC4207</gtr:id><gtr:name>Oxford Radcliffe Hospitals NHS Trust</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/57150975-2FFC-442F-A99E-ABD25A46F8D2"><gtr:id>57150975-2FFC-442F-A99E-ABD25A46F8D2</gtr:id><gtr:name>Pasteur Institute, Paris</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/224F438B-D9C4-4291-9A40-0AEFC75849FC"><gtr:id>224F438B-D9C4-4291-9A40-0AEFC75849FC</gtr:id><gtr:firstName>William</gtr:firstName><gtr:surname>Irving</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/AC598898-2621-408B-B5DC-3F99F0CB3462"><gtr:id>AC598898-2621-408B-B5DC-3F99F0CB3462</gtr:id><gtr:firstName>Jonathan</gtr:firstName><gtr:otherNames>Kelvin</gtr:otherNames><gtr:surname>Ball</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/7722E517-3613-45A4-87C1-A70864148BFA"><gtr:id>7722E517-3613-45A4-87C1-A70864148BFA</gtr:id><gtr:firstName>Lindy</gtr:firstName><gtr:surname>Durrant</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=G0801169"><gtr:id>6C427F68-3E2D-48EF-8270-86F856A98AAE</gtr:id><gtr:title>Human monoclonal antibodies for the treatment and prevention of hepatitis C virus infection</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0801169</gtr:grantReference><gtr:abstractText>Chronic Hepatitis C virus is a blood-borne infection that can result in development of very serious liver disease. The most severe forms of liver disease can only be treated by liver transplantation. Re-infection of the transplanted liver is often rapid and current treatments are ineffective in this group of patients. Alternative therapies are sought, particularly for this group of patients. Therefore, we will isolate human monoclonal antibodies from individuals who have naturally cleared virus. These antibodies will provide important lead therapies to prevent transplant re-infection and will also provide important information that will help vaccine design. An important aspect of this work will be to study how the virus changes during infection, so that those antibodies that target the widest range of virus strains are identified.</gtr:abstractText><gtr:technicalSummary>Hepatitis C virus (HCV) is the major causative agent of non-A, non-B hepatitis. HCV infection is found throughout the world and the prevalence of anti-HCV antibodies range from 0.2 to 2% in most developed countries. Acute HCV infection results in viral clearance in 20% of individuals and there is evidence that the patients who resolve infection harbour cross-reactive neutralising antibodies, whereas those who develop chronic infection do not. Evolution of viral quasispecies is also more rapid in individuals with chronic infection, yet its relationship to host antibody response is poorly understood. Here, we will isolate and characterise human monoclonal antibodies from individuals with acute infection and determine antibody correlates associated with clearance. We will also determine E1E2 glycoprotein gene evolution to define mechanisms of escape. This information will be important in defining the best epitopes to target in vaccine design. In addition, this project will also deliver monoclonal antibodies with significant therapeutic potential. End-stage liver disease is a frequent result of chronic HCV infection, and this requires liver transplantation. Long term prognosis is poor due to re-infection of the grafted liver and poor treatment outcomes in this group of patients. Therapeutic antibodies will have huge potential in this clinical setting. This proposal will provide essential foundation knowledge and lead compounds to help combat a disease of major public health importance, which is the principal cause of primary liver cancer.</gtr:technicalSummary><gtr:fund><gtr:end>2013-06-30</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2009-06-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>538878</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Karolinska Institute</gtr:collaboratingOrganisation><gtr:country>Sweden, Kingdom of</gtr:country><gtr:description>KIMoM modified E2</gtr:description><gtr:id>9357BD0A-E55D-46D7-A00A-4557B6E12104</gtr:id><gtr:impact>Patent application in progress</gtr:impact><gtr:partnerContribution>Provision of knnow how</gtr:partnerContribution><gtr:piContribution>Collaboration in the cloning of antibody variable regions</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Molecules of Man AB</gtr:collaboratingOrganisation><gtr:country>Sweden, Kingdom of</gtr:country><gtr:description>Preclinical antibody testing</gtr:description><gtr:id>896B9C2E-7AC4-4956-9568-C20BFF2E5099</gtr:id><gtr:impact>commercially sensitive</gtr:impact><gtr:partnerContribution>Provision of lead antibodies</gtr:partnerContribution><gtr:piContribution>Efficacy and synergy testing of monoclonal antibodies</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Pasteur Institute, Paris</gtr:collaboratingOrganisation><gtr:country>France, French Republic</gtr:country><gtr:department>Department of Virology</gtr:department><gtr:description>Pasteur-MoM-Vaccine</gtr:description><gtr:id>C4CEEDD0-822A-43A0-9CC7-ABF130771CD9</gtr:id><gtr:impact>Successful DPFS grant application</gtr:impact><gtr:partnerContribution>Advice and support on platform technologiesProvision and advice about platform technologies</gtr:partnerContribution><gtr:piContribution>We are developing lead vaccines targeting conserved HCV epitopes</gtr:piContribution><gtr:sector>Multiple</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>CEINGE Biotecnologie Avanzate</gtr:collaboratingOrganisation><gtr:country>Italy, Italian Republic</gtr:country><gtr:description>Conjugated antibodies</gtr:description><gtr:id>A2630957-30DB-4DD0-8BD2-0218ECA9BCFF</gtr:id><gtr:impact>Manuscript submitted</gtr:impact><gtr:partnerContribution>Provision of conjugated antibodies and technology and know-how</gtr:partnerContribution><gtr:piContribution>Testing the antiviral activity of conjugated antibodies</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>CEINGE Biotecnologie Avanzate</gtr:collaboratingOrganisation><gtr:country>Italy, Italian Republic</gtr:country><gtr:description>Trial of antibodies</gtr:description><gtr:id>35645136-98B3-420D-BA23-6CF6ABB15F78</gtr:id><gtr:impact>Role of scavenger receptor class B type I in hepatitis C virus entry: kinetics and molecular determinants. Catanese MT, Ansuini H, Graziani R, Huby T, Moreau M, Ball JK, Paonessa G, Rice CM, Cortese R, Vitelli A, Nicosia A. J Virol. 2010 Jan;84(1):34-43</gtr:impact><gtr:partnerContribution>Provision of reagents and know-how.</gtr:partnerContribution><gtr:piContribution>Pre- clinical testing of antibody efficacy.</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Molecules of Man AB</gtr:collaboratingOrganisation><gtr:country>Sweden, Kingdom of</gtr:country><gtr:description>Pasteur-MoM-Vaccine</gtr:description><gtr:id>A84D37CF-ACB3-4C39-9248-3466057F51EE</gtr:id><gtr:impact>Successful DPFS grant application</gtr:impact><gtr:partnerContribution>Advice and support on platform technologiesProvision and advice about platform technologies</gtr:partnerContribution><gtr:piContribution>We are developing lead vaccines targeting conserved HCV epitopes</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Oxford Radcliffe Hospitals NHS Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Weatherall Institute of Molecular Medicine (WIMM)</gtr:department><gtr:description>Ebola antibodies</gtr:description><gtr:id>4595978A-1E55-4241-ABBA-54BA9B01EA02</gtr:id><gtr:impact>This is an early collaborative venture in response to the W. African Ebolavirus outbreak</gtr:impact><gtr:partnerContribution>Provision of samples and analytical tools</gtr:partnerContribution><gtr:piContribution>Human monoclonal antibody discovery methods</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Radio packages</gtr:description><gtr:form>A broadcast e.g. TV/radio/film/podcast (other than news/press)</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>75D864F9-20C7-4973-9D28-47FA163F7870</gtr:id><gtr:impact>A series of radio packages produced by or involving JKB that were aired on BBC R4 and also BBC World Radio</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>School talk</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>93EB8577-F6E0-47BB-B801-98F0AC03F1DF</gtr:id><gtr:impact>30 A level pupils attended a talk on virology

staff reported back increased interest in microbiology and virology</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Nottingham MayFest</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>4A7DAA49-DC76-4F33-A01C-8544E3C56A8A</gtr:id><gtr:impact>6,000 people annually attend this public engagement festival. We offered a hands-on virus detective session that allowed members of the public to try out virology experiments.

Led to invited school talks</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Workshop Facilitator</gtr:presentationType><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>http://www.nottingham.ac.uk/mayfest/index.aspx</gtr:url><gtr:year>2011,2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Public Outreach Session</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>82BB58B8-DF92-4B9C-ADA9-4DD4AF328433</gtr:id><gtr:impact>Virology outreach talk</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>4900000</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>EUR</gtr:currCode><gtr:currCountryCode>Austria</gtr:currCountryCode><gtr:currLang>de_AT</gtr:currLang><gtr:description>EU FP7</gtr:description><gtr:end>2017-12-02</gtr:end><gtr:fundingOrg>European Commission (EC)</gtr:fundingOrg><gtr:fundingRef>305600</gtr:fundingRef><gtr:id>791CB72E-E6CA-46C1-B019-BACF0368C2B6</gtr:id><gtr:sector>Public</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>246000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>DPFS (University of Nottingham Portfolio)</gtr:description><gtr:end>2011-01-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>42ECF44B-6FE0-4847-90FC-8E62A4BCCE1A</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>5000000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>National Institute for Health Research (NIHR)</gtr:department><gtr:description>NIHR Biomedical Research Unit</gtr:description><gtr:fundingOrg>University College London Hospitals Charity (UCLH)</gtr:fundingOrg><gtr:id>5DEC5B00-2C8D-4281-B5AA-69345A23B16A</gtr:id><gtr:sector>Public</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>120000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>NIHR Biomedical Research Unit, Nottingham University Hospitals NHS Trust</gtr:department><gtr:description>Clinical Fellowship</gtr:description><gtr:end>2012-09-02</gtr:end><gtr:fundingOrg>National Institute for Health Research (NIHR)</gtr:fundingOrg><gtr:id>2C806265-69FB-4958-BE87-3E15D1416CE6</gtr:id><gtr:sector>Learned Society</gtr:sector><gtr:start>2009-06-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1300000</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>EUR</gtr:currCode><gtr:currCountryCode>Austria</gtr:currCountryCode><gtr:currLang>de_AT</gtr:currLang><gtr:description>EU Horizon 2020</gtr:description><gtr:end>2021-09-02</gtr:end><gtr:fundingOrg>European Commission</gtr:fundingOrg><gtr:id>45AD32EF-955B-4F6A-BE0B-0A912649B305</gtr:id><gtr:sector>Public</gtr:sector><gtr:start>2017-10-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>An expression library of E2 glycoproteins containing random point mutations for use in antibody epitope mapping.</gtr:description><gtr:id>FEB1275D-9083-433B-BE1D-3E5BAFFD0528</gtr:id><gtr:impact>No impacts have been achieved yet, but the library will greatly facilitate characterization of the epitopes recognized by the human monoclonal antibodies that we are isolating.</gtr:impact><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>RandomGlycoproteinMutantLibrary</gtr:title><gtr:type>Biological samples</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Our invention consists of recombinant HCV E2 glycoproteins that have been modified so that they can be used to selectively elicit or enrich for neutralising antibodies targeting novel epitopes.</gtr:description><gtr:id>CAD39431-35DC-42ED-AECE-4FF7E94E9E31</gtr:id><gtr:impact>The know-how is being used in a joint project aimed at isolating novel human antibodies and antibody fragments.</gtr:impact><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Modified viral glycoprotein</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:yearFirstProvided>2010</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Developed a technology for the production of bovine monoclonal antibodies</gtr:description><gtr:id>8E536632-6E9E-4775-AB4B-2D0E095C2AB7</gtr:id><gtr:impact>This method has just been finalized. We are planning to use this to generate MAbs for animal and human use as well as a tool for basic research. We are also scoping out development of a spin-out.</gtr:impact><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Bovine MAb production method</gtr:title><gtr:type>Technology assay or reagent</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Standardized E1E2 glycoprotein panel for neutralising antibody sensitivity testing</gtr:description><gtr:id>060D98EE-8FE5-4C73-9744-98570EF1C383</gtr:id><gtr:impact>Identification of broadly neutralizing antibodies and sera for future development as therapeutics and or for use in vaccine design</gtr:impact><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>E1E2 panel</gtr:title><gtr:type>Database/Collection of Data/Biological Samples</gtr:type><gtr:yearFirstProvided>2011</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/A21CCEF1-25DE-48AE-8B5E-5221072168A6"><gtr:id>A21CCEF1-25DE-48AE-8B5E-5221072168A6</gtr:id><gtr:title>The role of neutralizing antibodies in hepatitis C virus infection.</gtr:title><gtr:parentPublicationTitle>The Journal of general virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/33f1fec3ba6eb225193757971eb35531"><gtr:id>33f1fec3ba6eb225193757971eb35531</gtr:id><gtr:otherNames>Edwards VC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0022-1317</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/C3CCD515-733A-41B1-8CEB-1E4CA3415206"><gtr:id>C3CCD515-733A-41B1-8CEB-1E4CA3415206</gtr:id><gtr:title>Hepatitis C virus envelope glycoprotein fitness defines virus population composition following transmission to a new host.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/3e5bc1756e96e835a0772ea0b6c44eaa"><gtr:id>3e5bc1756e96e835a0772ea0b6c44eaa</gtr:id><gtr:otherNames>Brown RJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/2F777DB0-6E17-4C55-B645-B2C3973D03AF"><gtr:id>2F777DB0-6E17-4C55-B645-B2C3973D03AF</gtr:id><gtr:title>An ancestral host defence peptide within human ?-defensin 3 recapitulates the antibacterial and antiviral activity of the full-length molecule.</gtr:title><gtr:parentPublicationTitle>Scientific reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/63ed92c799ccafc2233be3b041e4e16b"><gtr:id>63ed92c799ccafc2233be3b041e4e16b</gtr:id><gtr:otherNames>Nigro E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2045-2322</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/7D18E9DF-8613-4B12-97C9-8EF67056E038"><gtr:id>7D18E9DF-8613-4B12-97C9-8EF67056E038</gtr:id><gtr:title>Analysis of serine codon conservation reveals diverse phenotypic constraints on hepatitis C virus glycoprotein evolution.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/3e5bc1756e96e835a0772ea0b6c44eaa"><gtr:id>3e5bc1756e96e835a0772ea0b6c44eaa</gtr:id><gtr:otherNames>Brown RJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/EDCBD9E2-F8A0-471E-B624-B066B346DEB5"><gtr:id>EDCBD9E2-F8A0-471E-B624-B066B346DEB5</gtr:id><gtr:title>Novel functional hepatitis C virus glycoprotein isolates identified using an optimized viral pseudotype entry assay.</gtr:title><gtr:parentPublicationTitle>The Journal of general virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/074173c0a663433a9cee5753743a937d"><gtr:id>074173c0a663433a9cee5753743a937d</gtr:id><gtr:otherNames>Urbanowicz RA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0022-1317</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/1657DED4-E208-45F3-BD51-6167617A3C82"><gtr:id>1657DED4-E208-45F3-BD51-6167617A3C82</gtr:id><gtr:title>Identification of new functional regions in hepatitis C virus envelope glycoprotein E2.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/7775bbaa6da982e8a293b5ef539fffe3"><gtr:id>7775bbaa6da982e8a293b5ef539fffe3</gtr:id><gtr:otherNames>Albecka A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/ECA360F8-ADB1-4276-B55E-78D1D014A038"><gtr:id>ECA360F8-ADB1-4276-B55E-78D1D014A038</gtr:id><gtr:title>Use of short tandem repeat fingerprinting to validate sample origins in hepatitis C virus molecular epidemiology studies.</gtr:title><gtr:parentPublicationTitle>The Journal of general virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/33f1fec3ba6eb225193757971eb35531"><gtr:id>33f1fec3ba6eb225193757971eb35531</gtr:id><gtr:otherNames>Edwards VC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0022-1317</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/3A1CB0A0-7470-4DC2-9EFD-E306BEBC8A31"><gtr:id>3A1CB0A0-7470-4DC2-9EFD-E306BEBC8A31</gtr:id><gtr:title>Hepatitis C patient-derived glycoproteins exhibit marked differences in susceptibility to serum neutralizing antibodies: genetic subtype defines antigenic but not neutralization serotype.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/fba3ccb5d5fdeb9fdfc12cfe1fdc3142"><gtr:id>fba3ccb5d5fdeb9fdfc12cfe1fdc3142</gtr:id><gtr:otherNames>Tarr AW</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/BF0A663E-1883-4B69-9A4D-DBCBE5873575"><gtr:id>BF0A663E-1883-4B69-9A4D-DBCBE5873575</gtr:id><gtr:title>Specific interaction of hepatitis C virus glycoproteins with mannan binding lectin inhibits virus entry.</gtr:title><gtr:parentPublicationTitle>Protein &amp; cell</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/03d703dcd06c9f41877473f2908d74e1"><gtr:id>03d703dcd06c9f41877473f2908d74e1</gtr:id><gtr:otherNames>Brown KS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1674-800X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/C71C16D3-44EE-44DD-B0C7-42E0F8B30E1D"><gtr:id>C71C16D3-44EE-44DD-B0C7-42E0F8B30E1D</gtr:id><gtr:title>Dramatic potentiation of the antiviral activity of HIV antibodies by cholesterol conjugation.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/c3bc6472de47e9229c86a690a4ea1e18"><gtr:id>c3bc6472de47e9229c86a690a4ea1e18</gtr:id><gtr:otherNames>Lacek K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/4D772776-C6F8-4CD7-A612-F1192A96BB01"><gtr:id>4D772776-C6F8-4CD7-A612-F1192A96BB01</gtr:id><gtr:title>Neutralizing monoclonal antibodies against hepatitis C virus E2 protein bind discontinuous epitopes and inhibit infection at a postattachment step.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/e73f6f147778fc731940f5d6efa8211a"><gtr:id>e73f6f147778fc731940f5d6efa8211a</gtr:id><gtr:otherNames>Sabo MC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/E4F2362B-ECBA-4F78-AE75-52475936B091"><gtr:id>E4F2362B-ECBA-4F78-AE75-52475936B091</gtr:id><gtr:title>Hepatitis C virus (HCV) infection may elicit neutralizing antibodies targeting epitopes conserved in all viral genotypes.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/2d1b485081fc412281859c3e3bf01094"><gtr:id>2d1b485081fc412281859c3e3bf01094</gtr:id><gtr:otherNames>Mancini N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/97DA5991-F422-47D1-98CC-DD939302B63F"><gtr:id>97DA5991-F422-47D1-98CC-DD939302B63F</gtr:id><gtr:title>Role of scavenger receptor class B type I in hepatitis C virus entry: kinetics and molecular determinants.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/db18e4526f96a1b1e6e1f0bfa798a84e"><gtr:id>db18e4526f96a1b1e6e1f0bfa798a84e</gtr:id><gtr:otherNames>Catanese MT</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/B89CF548-E58D-48E0-954A-44076289D4C1"><gtr:id>B89CF548-E58D-48E0-954A-44076289D4C1</gtr:id><gtr:title>The past, present and future of neutralizing antibodies for hepatitis C virus.</gtr:title><gtr:parentPublicationTitle>Antiviral research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/cd35d1b54c6b5cb7a796ed9ffb36be05"><gtr:id>cd35d1b54c6b5cb7a796ed9ffb36be05</gtr:id><gtr:otherNames>Ball JK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0166-3542</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/3E40AD0D-C3CD-4A57-B3B5-CF24E7913F26"><gtr:id>3E40AD0D-C3CD-4A57-B3B5-CF24E7913F26</gtr:id><gtr:title>The role of humoral innate immunity in hepatitis C virus infection.</gtr:title><gtr:parentPublicationTitle>Viruses</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/fba3ccb5d5fdeb9fdfc12cfe1fdc3142"><gtr:id>fba3ccb5d5fdeb9fdfc12cfe1fdc3142</gtr:id><gtr:otherNames>Tarr AW</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1999-4915</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/B2694073-4C88-4AE8-8C27-DCDECEEB00A3"><gtr:id>B2694073-4C88-4AE8-8C27-DCDECEEB00A3</gtr:id><gtr:title>Broad neutralization of hepatitis C virus-resistant variants by Civacir hepatitis C immunoglobulin.</gtr:title><gtr:parentPublicationTitle>Hepatology (Baltimore, Md.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/19b52ea49f5152e0dafb68cf0a572d60"><gtr:id>19b52ea49f5152e0dafb68cf0a572d60</gtr:id><gtr:otherNames>Tawar RG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0270-9139</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/F06B9DE8-19C9-4B5E-92ED-0725134E3B3B"><gtr:id>F06B9DE8-19C9-4B5E-92ED-0725134E3B3B</gtr:id><gtr:title>Hepatitis C virus quasispecies and pseudotype analysis from acute infection to chronicity in HIV-1 co-infected individuals.</gtr:title><gtr:parentPublicationTitle>Virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/92b19782b85ed8995b88c7c97e7ddffa"><gtr:id>92b19782b85ed8995b88c7c97e7ddffa</gtr:id><gtr:otherNames>Ferns RB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0042-6822</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/7B2B14CF-496C-4121-BEC5-252EB3B305A6"><gtr:id>7B2B14CF-496C-4121-BEC5-252EB3B305A6</gtr:id><gtr:title>Recombinant human L-ficolin directly neutralizes hepatitis C virus entry.</gtr:title><gtr:parentPublicationTitle>Journal of innate immunity</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/1a6fc5bf8c5e5f9ad96118810239904d"><gtr:id>1a6fc5bf8c5e5f9ad96118810239904d</gtr:id><gtr:otherNames>Hamed MR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1662-811X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/503134DE-3792-4C13-A3CF-FB96B0E02E3A"><gtr:id>503134DE-3792-4C13-A3CF-FB96B0E02E3A</gtr:id><gtr:title>Naturally occurring antibodies that recognize linear epitopes in the amino terminus of the hepatitis C virus E2 protein confer noninterfering, additive neutralization.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/fba3ccb5d5fdeb9fdfc12cfe1fdc3142"><gtr:id>fba3ccb5d5fdeb9fdfc12cfe1fdc3142</gtr:id><gtr:otherNames>Tarr AW</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/339671F0-D098-4C42-8301-A5CF2D7F007D"><gtr:id>339671F0-D098-4C42-8301-A5CF2D7F007D</gtr:id><gtr:title>A Diverse Panel of Hepatitis C Virus Glycoproteins for Use in Vaccine Research Reveals Extremes of Monoclonal Antibody Neutralization Resistance.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/074173c0a663433a9cee5753743a937d"><gtr:id>074173c0a663433a9cee5753743a937d</gtr:id><gtr:otherNames>Urbanowicz RA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/9145C2BB-E810-4946-9908-E2540A362D82"><gtr:id>9145C2BB-E810-4946-9908-E2540A362D82</gtr:id><gtr:title>Novel human anti-claudin 1 mAbs inhibit hepatitis C virus infection and may synergize with anti-SRB1 mAb.</gtr:title><gtr:parentPublicationTitle>The Journal of general virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/4ebd6dc2026d8921981d8c1aebd8349d"><gtr:id>4ebd6dc2026d8921981d8c1aebd8349d</gtr:id><gtr:otherNames>Paciello R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0022-1317</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/7B8EDF5E-13ED-456E-B2EF-E6F41AC25572"><gtr:id>7B8EDF5E-13ED-456E-B2EF-E6F41AC25572</gtr:id><gtr:title>Targeting a host-cell entry factor barricades antiviral-resistant HCV variants from on-therapy breakthrough in human-liver mice.</gtr:title><gtr:parentPublicationTitle>Gut</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/40bb6a0182ba7a2a1cb77d83e9eaaacd"><gtr:id>40bb6a0182ba7a2a1cb77d83e9eaaacd</gtr:id><gtr:otherNames>Vercauteren K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0017-5749</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/A10BA0B9-8D09-42A6-A681-037E5B8E1AF2"><gtr:id>A10BA0B9-8D09-42A6-A681-037E5B8E1AF2</gtr:id><gtr:title>Human Adaptation of Ebola Virus during the West African Outbreak.</gtr:title><gtr:parentPublicationTitle>Cell</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/074173c0a663433a9cee5753743a937d"><gtr:id>074173c0a663433a9cee5753743a937d</gtr:id><gtr:otherNames>Urbanowicz RA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0092-8674</gtr:issn></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0801169</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>03BA7BC9-C251-48FC-8EA9-5F7414A63FEE</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Infection</gtr:text></gtr:healthCategory><gtr:healthCategory><gtr:id>C6D70A71-8796-47BC-AFE0-CC2286E66A06</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Inflammatory and Immune System</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>